Receipt Of In-Principle Approval For Preferential Issue

Summary by 6ix AI

Aptus Pharma Ltd. has received in-principle approval for a preferential issue of equity shares from BSE Limited, as reported in this filing. The approval is in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations. The shareholders had previously approved this issue at their Annual General Meeting. A copy of the approval letter from BSE is included for reference.

Written by 6ix AI from the company’s filing. How 6ix writes summaries